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ProfileVSELs: Is Ideology Overtaking Science?The stem cell field is currently engaged in
a feisty debate about how to advance
innovative research while assuring that
clinical translation proceeds safely and
prudently. Every new approach comes
under scrutiny, but over recent years
broad claims about the properties and
potential of adult stem cell populations
have been a particular focus of concern.
In April, these issues rose to the fore
again when scientists at the University
of Michigan and New-York-based Neo-
Stem Inc. announced plans to launch
a first-in-man trial using very small
embryonic-like cells (VSELs) to regen-
erate bone. Many leading stem cell
researchers argue that this step is pre-
mature. The data on VSELs are much
less well established than they are for
mesenchymal stem cells, says George
Daley, Director of Stem Cell Transplanta-
tion at Children’s Hospital, Boston, and
yet no one to date has proven how to
harness MSCs to improve bone healing.
Outstanding questions abound, including
the very basic one of whether VSELs are
in fact cells at all, as opposed to subcel-
lular particles or debris. ‘‘If they have
found a new kind of cell with miraculous
properties, they certainly haven’t estab-
lished it in a rigorous way that’s been
convincing to the general community,’’
says Daley. Indeed, only a handful of
groups have published on VSELs, and
an almost equal number of groups have
published papers with negative results.
It’s a view echoed by Christine
Mummery, a professor of developmental
biology at Leiden University Medical
Center in the Netherlands. ‘‘They are
obviously measuring something. But it’s
difficult to say what,’’ she says. ‘‘As long
as these cells remain rather odd and the
experiments that are published seem
slightly less than robust, I think they’re
open to question.’’
Even Mariusz Ratajczak, director of the
developmental biology research program
at the University of Louisville’s James
Graham Brown Cancer Center and the
lead author of the paper that brought
VSELs into the literature, is anxious about
the pace at which they are being pushed.
‘‘I’m a little bit scared because I know that
NeoStem would like to go fast to theclinic,’’ he says. ‘‘I still think we need to
do more basic research.’’
Back in 2006, Ratajczak and his col-
leagues, who were working with mice,
were the first to describe a population of
small cells (around 3.6 mm in diameter)
with a thin rim of cytoplasm surrounding
a euchromatin-rich nucleus, and appar-
ently boasting a suite of molecular
markers characteristic of pluripotent
embryonic stem cells. In culture, these
cells, which they christened VSEL cells,
seemed capable of differentiation into all
three germ layer lineages, leading to the
suggestion that they ‘‘could be a source
of pluripotent stem cells for tissue/organ
regeneration.’’ (Reviewed in Kassmer
et al., 2013).
Since then, Ratajczak’s group and
others have described cells with a similar
morphological and molecular profile in
a broad range of murine tissues, from
cord blood and bone marrow to heart
and brain, and even in the reproductive
organs. Some studies have also sug-
gested that mouse VSELs are highly
mobile, with concentrations in the peri-
pheral blood escalating in response to a
range of insults, including myocardial
infarction, stroke, skin burns, and Crohn’s
disease (reviewed in Kassmer et al.,
2013).
When the University of Louisville began
to circulate the patents it had filed to pro-
tect the use of these cells for a range of
clinical indications, there was interest
from NeoStem, a biopharmaceutical
company with a focus on the therapeutic
potential of adult cells. ‘‘Our interest was
to see if these cells were present in
humans,’’ says Denis Rodgerson, founder
and Director of Stem Cell Science at
NeoStem, which acquired the worldwide
exclusive license to VSEL technology in
2007. ‘‘It was an intriguing opportunity.’’
NeoStem has developed a protocol for
the isolation and extraction of what they
present as an analogous population of
cells in humans and has filed around
20 patent applications protecting the
method for isolating these cells and ‘‘a
very broad swath of indications that one
could imagine using these cells for regen-
erative purposes,’’ says Todd Girolamo,
Associate General Counsel at NeoStem.Cell Stem Cell 1NeoStem and a range of partner institu-
tions have also obtained an estimated
$4.5 million in government grants—
notably from the Department of Defense
and NIH—to explore the potential of
human VSELs for regenerative medicine.
‘‘We have strong evidence suggesting
that these cells will differentiate into all
mesenchymal tissue in vivo,’’ says Rodg-
erson. Furthest along the development
pipeline, in partnership with researchers
at the University of Michigan, Ann Arbor,
is research into the differentiation of
VSELs into bone. Based on a paper pub-
lished in February (Havens et al., 2013),
NeoStem is planning to apply for FDA
approval to carry out a first-in-man trial us-
ing VSELs to regenerate bone following a
tooth extraction. ‘‘We certainly want to
demonstrate with this first-in-man trial
the safety of these V[SEL] cells,’’ says
Tim Fong, NeoStem’s Vice President for
Technology and Product Development.
‘‘This will make it easier to think about
establishing clinical efficacy and the other
indications that NeoStem is interested in.’’
But many in the wider stem cell com-
munity remain unconvinced. ‘‘To make a
robust claim for a new type of ‘embry-
onic-like’ cell, you come at it every which
way from Sunday,’’ says Daley. ‘‘This
rigorous approach just hasn’t been taken
with VSELs. I find the work mystifying
and lacking in rigor.’’ The relationship
that NeoStem has forged with the Vatican
through the Stem for Life Foundation
(a not-for-profit organization set up by
NeoStem to promote the potential of
adult stem cells) has also influenced the
wider perception of the company and
its research. A recent editorial in Nature
(Nature, 2013) was scathing about a
meeting organized by the Stem for Life
Foundation in Vatican City in April: ‘‘Sick
children were paraded for television,
sharing the stage with stem cell com-
panies and scientists desperate to hawk
a message that their therapies must be
speeded to clinical use.’’ Some in the
field have also raised concerns about
the potential for the Vatican to exert
influence over the scientific focus of
Neostem through this connection.
Chris Mason, Chair of Regenerative
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and begs to differ. ‘‘I was very cautious
before I accepted the invitation,’’ he
says. ‘‘But I did actually see a genuine
meeting and genuine dialogue. Unfortu-
nately a lot of the reporting made about
that conference was by people who did
not attend.’’ That said, there are still a lot
of unanswered questions about VSELs,
saysMason. ‘‘It’s all about reproducibility.
We need to see more standards, more
characterization, and more common
assays used that enable us to compare
these different cell types and to really
know what they do.’’
Recent publications have underscored
these concerns. For one study, Vita34, a
private cord blood bank in Germany,
teamed up with researchers at the
University of Leipzig to isolate human
VSELs from some of their banked sam-
ples. In the resulting paper, they claimed
to have isolated human VSELs, reporting
that they ‘‘failed to expand in vitro under
a wide range of culture conditions known
to support embryonic or adult stem cell
types’’ (Danova-Alt et al., 2012). ‘‘We
would have found them if they were
there,’’ asserts Ru¨diger Alt, lead author
on the paper and now head of research
and development at Vita34. ‘‘If they had
any sort of proliferative capacity, it should
have turned out in our assays, but it
didn’t.’’ Based on this analysis Vita34 is
no longer pursuing research into these
cells, he says.
For Ratajczak, there is a simple expla-
nation. ‘‘In studying rare populations of
cells, one needs to compare apples to
apples, which unfortunately was not
done,’’ he says. ‘‘They did not follow our
isolation protocol. All the experiments
they performed were performed on the
wrong population of cells.’’ Ratajczak is
similarly dismissive of a study that
appeared earlier this year that called into
question the reported properties of
VSELs, this time in mice (Szade et al.,
2013), and he cites another study claiming144 Cell Stem Cell 13, August 1, 2013 ª2013to demonstrate the differentiation of
VSELs into lung tissue in mice (reviewed
in Kassmer et al., 2013). But an even
more recent paper—the most robust
effort yet to replicate the isolation of
VSELs in mice—may be harder to
dismiss. ‘‘We found that every step of
the way, we could not confirm the results
of the Ratajczak group,’’ says Irving
Weissman, Director of the Stanford
Institute of Stem Cell Biology and
Regenerative Medicine and the senior
author of the article in Stem Cell Reports
(Miyanishi et al., 2013). As a result,
Weissman argues that clinical investiga-
tion of VSELs is misguided and may be
driven more by ideological or commercial
hopes for adult (as opposed to embry-
onic) stem cells than by robust scientific
support.
Daley would like to see a rapid resolu-
tion to this stalemate. ‘‘The folks who
are making negative claims should be
encouraged to contact the original lab to
refine the isolation protocols,’’ he says.
But, he adds, ‘‘it should be incumbent
upon Ratajczak to share the protocol in
a way that’s robust and reproducible. It
doesn’t do the field any good if only one
lab has the right hocus pocus to make a
technique work.’’
Daley cites technical concerns about
many aspects of the original VSEL work,
which claimed the cells were pluripotent
and yet lacked a clear-cut comparison
to verified pluripotent stem cells. He
would like to see proponents of VSELs
use the most rigorous experimental ap-
proaches available, such as pluripotent
reporter gene expression and lineage
tracing in mice, and work with others to
ensure reproducibility before moving for-
ward with any type of clinical application.
‘‘Is there a real pluripotent cell here that
can be cultured, expanded, and har-
nessed for therapeutic potential?’’ asks
Daley. ‘‘Or are they chasing cellular con-
taminants that can’t be easily exploited
for clinical application?’’Elsevier Inc.Despite such questions, NeoStem
intends to proceed. ‘‘I don’t think it’s
unusual that you have conflicting or
controversial data in a field that, in my
opinion, is still relatively early in terms of
understanding and fully characterizing
human V[SEL] cells,’’ says Fong. ‘‘The
proof will be in the clinical trials that will
hopefully come in the future.’’
But for others in the wider stem cell
field, the pace at which VSELs are being
pushed is a cause of considerable
concern. ‘‘We need more independent
validation of VSELs before clinical intro-
duction,’’ says Mummery. ‘‘If these un-
proven technologies are pushed too
hard commercially, there is a real danger
that it will raise the expectations of the
public. This could be very damaging to
the field as a whole.’’Henry Nicholls*
London, UK
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